The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cells

Persistent infection with high-risk human papillomavirus (HPV) is the primary contributor to the development of cervical cancer. Although HPV oncoproteins E6 and E7 clearly trigger cervical tumorigenesis by inactivating p53 and Rb pathways, the downstream mediators of p53/Rb inactivation remain elus...

Full description

Saved in:
Bibliographic Details
Main Authors: Qing Zhou, Hongfei Yu, Anliang Dong, Jiani Yi, Jia Li, Xufan Li, Liyuan Zhou, Qiongzi Qiu, Bingjian Lu, Honghe Zhang, Weiguo Lu, Yi Sun, Pengyuan Liu, Yan Lu
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558625000892
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850079374595850240
author Qing Zhou
Hongfei Yu
Anliang Dong
Jiani Yi
Jia Li
Xufan Li
Liyuan Zhou
Qiongzi Qiu
Bingjian Lu
Honghe Zhang
Weiguo Lu
Yi Sun
Pengyuan Liu
Yan Lu
author_facet Qing Zhou
Hongfei Yu
Anliang Dong
Jiani Yi
Jia Li
Xufan Li
Liyuan Zhou
Qiongzi Qiu
Bingjian Lu
Honghe Zhang
Weiguo Lu
Yi Sun
Pengyuan Liu
Yan Lu
author_sort Qing Zhou
collection DOAJ
description Persistent infection with high-risk human papillomavirus (HPV) is the primary contributor to the development of cervical cancer. Although HPV oncoproteins E6 and E7 clearly trigger cervical tumorigenesis by inactivating p53 and Rb pathways, the downstream mediators of p53/Rb inactivation remain elusive. Here we report that CDT2, a subunit of Cullin-RING ligase 4 (CRL4), is significantly upregulated in cervical carcinoma tissues, which correlates with E6/E7 expression and poor patient survival. Mechanistically, E7-mediated Rb degradation upregulates E2F1, which in turn increases CDT2 transcription, whereas E6-mediated p53 degradation downregulates TRIM22, a novel E3 ligase for CDT2 degradation, leading to CDT2 accumulation to promote growth and survival of cervical cancer cells. Importantly, CDT2 depletion induces DNA aneuploidy and senescence via stabilization of histone lysine methyltransferase SET8, a CRL4CDT2 substrate, acting as a tumor suppressor. Collectively, the TRIM22-CDT2-SET8 axis is the key mediator of the p53/Rb signals in regulation of growth and survival of HPV-positive cervical carcinoma cells, Thus, CDT2 could serve as a prognostic biomarker and therapeutic target for these carcinomas.
format Article
id doaj-art-f2bd8a632eff4f5daf40c5c077f5bb5f
institution DOAJ
issn 1476-5586
language English
publishDate 2025-09-01
publisher Elsevier
record_format Article
series Neoplasia: An International Journal for Oncology Research
spelling doaj-art-f2bd8a632eff4f5daf40c5c077f5bb5f2025-08-20T02:45:14ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55862025-09-016710121110.1016/j.neo.2025.101211The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cellsQing Zhou0Hongfei Yu1Anliang Dong2Jiani Yi3Jia Li4Xufan Li5Liyuan Zhou6Qiongzi Qiu7Bingjian Lu8Honghe Zhang9Weiguo Lu10Yi Sun11Pengyuan Liu12Yan Lu13Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Department of Gynecologic Oncology, Women’s Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, PR ChinaResearch Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, PR China; Cancer Institute of the 2nd Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, PR ChinaZhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Department of Gynecologic Oncology, Women’s Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, PR ChinaKey Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Sir Run Run Shaw Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, PR ChinaKey Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Sir Run Run Shaw Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, PR ChinaKey Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Sir Run Run Shaw Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, PR ChinaKey Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Sir Run Run Shaw Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, PR ChinaZhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Department of Gynecologic Oncology, Women’s Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, PR ChinaZhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Department of Gynecologic Oncology, Women’s Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, PR ChinaDepartment of Pathology, Research Unit of Intelligence Classification of Tumor Pathology and Precision Therapy, Chinese Academy of Medical Sciences, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, PR ChinaZhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Department of Gynecologic Oncology, Women’s Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, PR ChinaResearch Center for Life Science and Human Health, Binjiang Institute of Zhejiang University, Hangzhou 310053, PR China; Cancer Institute of the 2nd Affiliated Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, PR China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310013, PR China; Corresponding authors.Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Sir Run Run Shaw Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, PR China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310013, PR China; Corresponding authors.Zhejiang Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Department of Gynecologic Oncology, Women’s Hospital and Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, PR China; Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310013, PR China; Corresponding authors.Persistent infection with high-risk human papillomavirus (HPV) is the primary contributor to the development of cervical cancer. Although HPV oncoproteins E6 and E7 clearly trigger cervical tumorigenesis by inactivating p53 and Rb pathways, the downstream mediators of p53/Rb inactivation remain elusive. Here we report that CDT2, a subunit of Cullin-RING ligase 4 (CRL4), is significantly upregulated in cervical carcinoma tissues, which correlates with E6/E7 expression and poor patient survival. Mechanistically, E7-mediated Rb degradation upregulates E2F1, which in turn increases CDT2 transcription, whereas E6-mediated p53 degradation downregulates TRIM22, a novel E3 ligase for CDT2 degradation, leading to CDT2 accumulation to promote growth and survival of cervical cancer cells. Importantly, CDT2 depletion induces DNA aneuploidy and senescence via stabilization of histone lysine methyltransferase SET8, a CRL4CDT2 substrate, acting as a tumor suppressor. Collectively, the TRIM22-CDT2-SET8 axis is the key mediator of the p53/Rb signals in regulation of growth and survival of HPV-positive cervical carcinoma cells, Thus, CDT2 could serve as a prognostic biomarker and therapeutic target for these carcinomas.http://www.sciencedirect.com/science/article/pii/S1476558625000892Cervical cancerCDT2HPVsenescenceTRIM22SET8
spellingShingle Qing Zhou
Hongfei Yu
Anliang Dong
Jiani Yi
Jia Li
Xufan Li
Liyuan Zhou
Qiongzi Qiu
Bingjian Lu
Honghe Zhang
Weiguo Lu
Yi Sun
Pengyuan Liu
Yan Lu
The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cells
Neoplasia: An International Journal for Oncology Research
Cervical cancer
CDT2
HPV
senescence
TRIM22
SET8
title The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cells
title_full The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cells
title_fullStr The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cells
title_full_unstemmed The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cells
title_short The TRIM22-CDT2 axis is the key mediator of the p53-Rb signals in growth control of HPV-positive cervical carcinoma cells
title_sort trim22 cdt2 axis is the key mediator of the p53 rb signals in growth control of hpv positive cervical carcinoma cells
topic Cervical cancer
CDT2
HPV
senescence
TRIM22
SET8
url http://www.sciencedirect.com/science/article/pii/S1476558625000892
work_keys_str_mv AT qingzhou thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT hongfeiyu thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT anliangdong thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT jianiyi thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT jiali thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT xufanli thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT liyuanzhou thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT qiongziqiu thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT bingjianlu thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT honghezhang thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT weiguolu thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT yisun thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT pengyuanliu thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT yanlu thetrim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT qingzhou trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT hongfeiyu trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT anliangdong trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT jianiyi trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT jiali trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT xufanli trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT liyuanzhou trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT qiongziqiu trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT bingjianlu trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT honghezhang trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT weiguolu trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT yisun trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT pengyuanliu trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells
AT yanlu trim22cdt2axisisthekeymediatorofthep53rbsignalsingrowthcontrolofhpvpositivecervicalcarcinomacells